DELRAY BEACH, Fla., March 5, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today that it has finalized its first-in-class development of a fully synthetic glucose sensing system to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas.
